课题基金 / 基金详情

C/EBPJ3 in bone marrow stromal cell-mediated drug resistance of multiple myeloma

C/EBPJ3 in bone marrow stromal cell-mediated drug resistance of multiple myeloma
C/EBPJ3在骨髓基质细胞介导的多发性骨髓瘤耐药中的作用
批准号:
10618417
负责人:
Gangqing Hu
金额:
$26.32万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-04-25 至 2023-06-30

项目摘要

项目成果

Gangqing Hu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Epigenetic regulation plays a critical role in numerous biological processes. The overarching goal of my laboratory is to understand epigenetic mechanisms of drug resistance of hematological cancers in the bone marrow (BM) microenvironment. I have over 12 years of research experience on transcription regulation of chromatin regulators in immune cells, embryonic stem cells, and cancer cells. This proposal is to investigate the transcription-regulatory role of a leucine-zipper TF C/EBPβ in promoting de novo drug resistance of Multiple Myeloma (MM) in the BM microenvironment. MM is a disease caused by malignant plasma B cells mainly proliferating in the BM. It is incurable largely because of the emergence of drug resistance after treatments. One important contribution to drug resistance stems from the protective effect of the BM microenvironment, which includes growth promoting soluble factors and physical interaction with cellular components such as stromal cells and osteoblasts. The emergence of de novo drug resistance occurs in a short timeframe and is reversible, suggesting epigenetic mechanisms as an important contributor. However, the identities and mechanisms of chromatin regulators contributing to de novo drug resistance of MM in the BM microenvironment remain largely unexplored. Our preliminary results indicated C/EBPβ as a key transcription regulator of target genes of signaling pathways activated by BM stromal cells. The BM stromal cells induced a genome-wide reprogramming in gene expression (transcriptome) and chromatin accessibility (regulome) of MM cells, turned out being mainly driven by soluble factors. Integrative analysis with ENCODE genomic binding data indicated C/EBPβ as a major contributor to the BM stromal cellinduced transformation of transcriptome and regulome. As C/EBPβ- overexpression protects MM cells from IMiD compounds, our preliminary results defined C/EBPβ as a promising and new research subject to understand epigenetic mechanisms for the emergence of de novo drug resistance in MM. We hypothesize that C/EBPβ contributes to soluble factor-mediated drug resistance by transcriptionally regulating target genes of growth-promoting signaling pathways activated by BM stromal cells through
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
C/EBPJ3 in bone marrow stromal cell-mediated drug resistance of multiple myeloma
  • 批准号:
    10620611
  • 项目类别:
  • 资助金额:
    $26.37万
  • 财政年份:
    2018
  • 负责人:
    Gangqing Hu
  • 依托单位:
C/EBPβ in bone marrow stromal cell-mediated drug resistance of multiple myeloma
  • 批准号:
    10709274
  • 项目类别:
  • 资助金额:
    $23.78万
  • 财政年份:
    2018
  • 负责人:
    Gangqing Hu
  • 依托单位:
国内基金
海外基金
骨病多模态报告和数据系统(Bone-RADS):规范精准风险评估并优化诊疗管理建议的临床研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    5.0万元
  • 批准年份:
    2024
  • 负责人:
    钟京谕
  • 依托单位:
酶响应的中性粒细胞外泌体载药体系在眼眶骨缺损修复中的作用及机制研究
  • 批准号:
    82371102
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    苏蕴
  • 依托单位:
精氨酸调控骨髓Tregs稳态在脓毒症骨髓功能障碍中的作用研究
  • 批准号:
    82371770
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    宁铂涛
  • 依托单位:
慢性炎症诱发骨丢失的机制及外泌体靶向治疗策略研究
  • 批准号:
    82370889
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    傅德皓
  • 依托单位: